HUMULIN R

(Insulin, human)

Approved

BBaxter Healthcare Corporation

HUMULIN R is one of 7 biologic programs targeting Postoperative Delirium (POD). It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Postoperative Delirium (POD)Not yet recruiting

Dry EyeCompleted

Postoperative Delirium (POD)Preclinical

Not yet recruiting

Dry EyeApproved

Completed

Competition

Competitive Landscape

10 competitors in Dry Eye

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

1 2

HUMULIN R

BBaxter Healthcare Corporation

Approved

1 3

Vevye

Roche

Phase 3

1 4

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 5

Diquafosol Tetrasodium

Merck & Co.

Preclinical

1 6

SYSTANE ULTRA Lubricant Eye

AAlcon Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Postoperative Delirium (POD)

NCT07720479

Clinical

Trials by Indication[1]

Dry Eye1 trial

Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease

Completed·KKhyber Teaching Hospital·Approved·NCT06939959·128 enrolled

Postoperative Delirium (POD)1 trial

Intranasal Insulin for Prevention of Postoperative Delirium in Older Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Not yet recruiting·WWeidong Mi·Preclinical·NCT07720479·210 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 28, 1982

HUMULIN R

BLA BLA018780

Oct 28, 1982

HUMULIN N

BLA BLA018781

Apr 25, 1989

HUMULIN 70/30

BLA BLA019717

Jun 27, 2014

AFREZZA

BLA BLA022472

Jun 20, 2019

MYXREDLIN

BLA BLA208157

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Insulin, human. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulin, human compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulin, human. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA208157). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

HUMULIN R

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Dry Eye1 trial

Postoperative Delirium (POD)1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News